Recent discussions on X about West Pharmaceutical Services (WST) have centered around the company’s latest earnings report, which exceeded expectations for both sales and earnings. Posts on the platform highlight the company’s raised full-year guidance, with some users noting the strong growth driven by demand for injectable drug delivery systems, particularly in the GLP-1 category. The stock’s significant surge post-earnings, even retaking key technical levels, has sparked lively engagement among investors.
However, not all reactions on X are uniformly positive, as some posts point to a sharp drop in stock price despite the earnings beat, with a few describing the market reaction as an overreaction. There’s a mix of optimism about the company’s fundamentals and caution regarding potential headwinds like destocking and operational challenges mentioned in analyst reports. This dynamic has kept the conversation intense and multifaceted across the platform.
Note: This discussion summary was generated from an AI condensation of post data.
West Pharmaceutical Services Congressional Stock Trading
Members of Congress have traded $WST stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $WST stock by members of Congress over the last 6 months:
- REPRESENTATIVE ROBERT BRESNAHAN has traded it 2 times. They made 1 purchase worth up to $15,000 on 02/25 and 1 sale worth up to $15,000 on 04/08.
- REPRESENTATIVE JARED MOSKOWITZ sold up to $15,000 on 02/13.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
West Pharmaceutical Services Hedge Fund Activity
We have seen 351 institutional investors add shares of West Pharmaceutical Services stock to their portfolio, and 367 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALLIANCEBERNSTEIN L.P. removed 2,512,343 shares (-96.9%) from their portfolio in Q1 2025, for an estimated $562,463,350
- DURABLE CAPITAL PARTNERS LP added 935,721 shares (+146.8%) to their portfolio in Q1 2025, for an estimated $209,489,217
- ARTISAN PARTNERS LIMITED PARTNERSHIP removed 915,420 shares (-29.4%) from their portfolio in Q1 2025, for an estimated $204,944,229
- VAN ECK ASSOCIATES CORP added 758,355 shares (+110.0%) to their portfolio in Q1 2025, for an estimated $169,780,517
- BROWN ADVISORY INC added 716,442 shares (+28.1%) to their portfolio in Q1 2025, for an estimated $160,397,034
- BLACKROCK, INC. removed 520,601 shares (-7.0%) from their portfolio in Q1 2025, for an estimated $116,552,151
- TWO SIGMA INVESTMENTS, LP added 446,839 shares (+588.0%) to their portfolio in Q1 2025, for an estimated $100,038,315
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
West Pharmaceutical Services Analyst Ratings
Wall Street analysts have issued reports on $WST in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Evercore ISI Group issued a "Outperform" rating on 07/25/2025
- UBS issued a "Buy" rating on 07/25/2025
- Keybanc issued a "Overweight" rating on 02/14/2025
To track analyst ratings and price targets for West Pharmaceutical Services, check out Quiver Quantitative's $WST forecast page.
West Pharmaceutical Services Price Targets
Multiple analysts have issued price targets for $WST recently. We have seen 4 analysts offer price targets for $WST in the last 6 months, with a median target of $322.5.
Here are some recent targets:
- Daniel Markowitz from Evercore ISI Group set a target price of $350.0 on 07/25/2025
- John Sourbeer from UBS set a target price of $320.0 on 07/25/2025
- Luke Sergott from Barclays set a target price of $245.0 on 06/24/2025
- Paul Knight from Keybanc set a target price of $325.0 on 02/14/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.